Bayer HealthCare's whistle-blowing sales rep finally got a job offer at his old company. Thing is, that offer was 500 miles away from home--and a U.S. judge was none too impressed with the gambit.
Debiotech has gained an option with Oregon-based iSense CGM to acquire exclusive rights to use its continuous glucose monitoring technology with patch insulin pumps for diabetes treatment. The companies expect that the integration of Debiotech's Jewel Pump with the iSense continuous glucose monitor technology could lead to the creation of an accurate artificial pancreas--a device that continuously measures insulin levels and then automatically dispenses insulin accordingly in response.
Bayer responded to an article in The New York Times critical of the company's Essure contraceptive inserts with a letter to the editor that claims the story "mischaracterizes" a recently published long-term study of the device.
Doubling down on its in-house startup academy, biotech VC stalwart Flagship Ventures has recruited a trio of big-name corporate sponsors to lend their expertise to its next class of seedlings, expanding its focus well beyond traditional drug development.
Bayer Healthcare is stepping up with $155 million in cash and a big near-term milestone in exchange for the development and commercialization rights to an experimental anticoagulant from Isis Pharmaceuticals.
Under investigation by the FDA following claims of dangerous side effects and fraudulent clinical trial data, Bayer has released new data from a long-term study the German drugmaker says supports the safety and effectiveness of its Essure contraceptive inserts.
The average upfront value in biotech deals hit a 9-year peak in 2014, according to Morrison & Foerster, part of a virtuous cycle in life sciences that has pushed asset valuations ever upward.
Large pharma companies are posting 530% more tweets a week than in 2013, a study by Ogilvy Healthworld found. The healthcare communications group tracked the social media activity of 14 large pharma companies for one week per month over three months.
Bayer had hoped to sell a veterinary med plant in Missouri that it picked up a few years ago from Teva. But no one has come forward, so the German drugmaker will close the plant and lay off 130 people.
Fitch Ratings is raising the flag on pharma M&A. The credit ratings agency says the current spate of dealmaking is putting some pressure on European Big Pharma players.